Clinical Trials Logo
  1. Home
  2. Non-small-cell Lung
  3. NCT03766490

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung Clinical Trial

Official title:
A Prospective, Single-arm, Multicenter Study of Anlotinib Hydrochloride Combined With First-generation EGFR TKIs as Second-line Treatment in Acquired (Non-T790M Mutation) Resistance Advanced Non-small Cell Lung Cancer

Clinical Trial Summary

After the second-line treatment of patients with non-T790M mutations, chemotherapy with platinum-containing drugs was used, and chemotherapy-related toxicity was high. Studies have shown that bevacizumab combined with EGFR TKI have a good trend of benefit. This study is aimed to evaluate the efficacy and safety of Anlotinib Hydrochloride combined with first-generation EGFR TKIs as second-line treatment in advanced non-small cell lung cancer . The patients with IV non-small lung cancer have acquired resistance to prior first-generation EGFR TKIs and have non-T790M mutation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03766490
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Min Tao, Doctor
Phone 008613962125300
Email taomin@suda.edu.cn
Status Not yet recruiting
Phase N/A
Start date March 30, 2019
Completion date December 20, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04362072 - Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer Phase 4
Terminated NCT03626545 - Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy Phase 3
Not yet recruiting NCT03389256 - Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC Phase 2
Active, not recruiting NCT03952403 - A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 3
Recruiting NCT05261399 - Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment Phase 3
Completed NCT00034879 - Iressa Expanded Access Program (EAP) Phase 3
Not yet recruiting NCT05465733 - First-line Replacement Maintenance of Envafolimab in Advanced NSCLC Phase 2
Active, not recruiting NCT03456063 - A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) Phase 3
Completed NCT00863746 - A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). Phase 3